Experimental autoimmune uveitis and other animal models of uveitis: An update

Svati Bansal¹, Veluchamy A. Barathi²,³,⁴, Daiju Iwata⁵, Rupesh Agrawal¹,²,⁶

Over the past several decades, animal models of autoimmune uveitis directed at eye-specific antigens (Ags) have been developed. These have allowed researchers to understand the basic mechanisms that lead to these diseases and also recently helped the researchers in translational research for therapeutic interventions. Experimental autoimmune uveitis (EAU) is an animal disease model of human endogenous uveitis and can be induced in susceptible animals by immunization with retinal Ags. Ever since the first description of EAU in mice in 1988, several animal models of uveitis has been described by researchers. Disease-specific model for cytomegalovirus retinitis and tubercular uveitis has evolved our understanding of these complex entities. Endotoxin induced uveitis is another useful model for anterior uveitis, which is not an autoimmune process and is triggered by injection of bacterial endotoxin (lipopolysaccharides) resulting in a rapid short lasting uveitis. The current article will give an insight into the various EAU animal models and their current implications in translational research. The article will also highlight the different grading systems for EAU in the animal model.

Key words: Animal uveitis model, cytomegalovirus retinitis animal model, endotoxin-induced uveitis, experimental autoimmune uveitis, spontaneous, tubercular uveitis animal model

Uveitis is a general term used for the inflammation of the uveal tissue (iris, ciliary body, and choroid). Anatomically it has been classified as anterior, intermediate and posterior or as panuveitis. Noninfectious uveitis is believed to be autoimmune or immune-mediated.[¹] Although the distinction between autoimmune and immune-mediated uveitis is still indistinct, the autoimmune type is believed to be driven by aberrant immune recognition of self, whereas the immune-mediated is primarily an inflammatory reaction triggered by environmental (microbial) or autologous (tissue damage) signals. Uveitis, especially if untreated, can result in significant visual deficit and blindness. It accounts for 5–20% of blindness in the developed countries and 25% in the developing countries.[²]

In idiopathic uveitis, the possible mechanism hypothesized is of molecular mimicry with common micro-organisms, but the etiological triggers in autoimmune uveitis are unknown. However, strong major histocompatibility complex (MHC) associations have been found to be linked with some of the different types of autoimmune uveitis [Table 1].

Patients with autoimmune uveitis frequently show immune responses targeted to ocular antigens (Ags) such as uveal melanin and proteins involved in its metabolism like retinal arrestin (retinal soluble antigen or [S-Ag]), inter-phoreceptor retinoid-binding protein (IRBP), and recoverin.[³,⁴]

The delicate nature of ocular tissues makes it difficult to obtain tissue specimens. This had greatly hampered the study of the mechanisms involved in uveitic disease. However, over the past several decades, animal models of autoimmune uveitis directed at eye-specific Ags have been developed.[⁵,⁶] These have allowed researchers to understand the basic mechanisms that lead to these diseases. Historically the first such model was prepared in guinea pigs by injecting the retinal extracts. This resulted in very severe panuveitis. This model, over a span of several years and after various modifications in terms of animal species and usage of other Ags, has led to the development of what is now known as experimental autoimmune uveitis (EAU).

Experimental Autoimmune Uveitis

What is experimental autoimmune uveitis?

Experimental autoimmune uveitis (EAU) is an animal disease model of human endogenous uveitis. It can be induced in susceptible animals by immunization with retinal Ags. EAU resembles the key immunological characteristics of uveitis in humans as both are T-cell mediated diseases (Th1) targeting the neural retina and related tissues. EAU is induced by immunization with preparation of purified retinal Ags or their fragments.

The uveitogenic retinal proteins identified so far are as follows:

- Retinal soluble antigen, arrestin

This 48-kDa intracellular photoreceptor protein is involved in the photo-transduction cascade. It binds to photo-activated phosphorylated rhodopsin, thereby apparently preventing the transducin-mediated activation of phosphodi-esterase.[⁷]

¹National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore, ²Singapore Eye Research Institute, Singapore, ³Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, ⁴SRP Neuroscience and Behavioral Disorder, DUKE-NUS Graduate Medical School, Singapore, ⁵Department of Ophthalmology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁶Institute of Ophthalmology, University College London, London

Correspondence to: Dr. Rupesh Agrawal, Consultant National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore 308433. E-mail: rupesh_agrawal@ttsh.com.sg

Manuscript received: 06.10.14; Revision accepted: 18.02.15
Table 1: HLA association of different ocular inflammatory conditions[5]

| Disease                        | Association       |
|-------------------------------|-------------------|
| BRC                           | HLA-A29           |
| VKH disease                   | HLA-DR4           |
| Behcet’s disease              | HLA-B51           |
| Intermediate uveitis (except  | HLA-DR3           |
| associated with multiple      |                   |
|    sclerosis)                  |                   |

HLA: Human leukocyte Ag, VKH: Vogt Koyanagi Harada, BRC: Birdshot retinochoroidopathy

**Inter-photoreceptor retinoid-binding protein**

This 148-kDa protein is found in the inter-photoreceptor matrix, which helps in transporting Vitamin A derivatives between the photoreceptor and the retinal pigment epithelium (RPE). IRBP is composed of four evolutionary conserved homologous domains, which are thought to have arisen by gene duplication.[9]

**Rhodopsin and its illuminated form – opsin**

This 40-kDa membrane protein is the rod visual pigment.[10] Pathogenicity of this protein appears to be conformation dependent as rhodopsin is more pathogenic than opsin.[11]

**Recoverin**

It is a 23-kDa calcium-binding protein. Recoverin controls the phosphorylation of the visual receptor rhodopsin by inhibiting rhodopsin kinase in photoreceptor cells.[12]

**Phosducin**

It is a 33-kDa soluble cytosolic photoreceptor protein and regulates the G-protein mediated signaling in the retina.[13] Out of all the above, the S-Ag and the IRBP are the most commonly used uveitogenic Ags for the EAU model.[14]

**Animal model for experimental autoimmune uveitis**

Experimental autoimmune uveitis can be induced in a variety of species including rats, mice, monkeys, guinea pigs and rabbits.[15,16] No animal model in itself represents the complete spectrum of human uveitis. Each has a unique characteristic that makes it suitable for the study of a particular disease aspect. The rat model combines the advantage of being average sized and well characterized immunologically and immuno-genetically.[5] The Lewis rat is especially susceptible to develop diseases when challenged with retinal Ags.[5] The Lewis strain has been hence particularly useful in studying uveitis due to its susceptibility to different Ags. The most susceptible strain of mouse is B10.R111, followed by B10.A. The C57BL/6 strain is useful to study the basic mechanism of uveitis. EAU in Lewis rats is an acute, self-limiting disease, which does not recur, however, in B10.A mouse a recurring form of the disease is seen.[5]

**Method of induction of experimental autoimmune uveitis**

The classic EAU model of mice, as reported in 1988 and modified later[14],[17] was induced with IRBP. For induction of EAU, IRBP is emulsified in complete Freund’s adjuvant (CFA), which consists of a suspension of tuberculosis bacteria in mineral oil. CFA is critical for inducing the disease in both mice and rats. Many mouse and rat strains also require an additional inflammatory stimulus in the form of pertussis toxin.[17] Following intradermal immunization with CFA the animals develop panuveitis in 1–2 weeks. The role of the adjuvant is to trigger a Th1 like response. The main features of EAU in animals are retinal and/or choroidal inflammation, retinal vasculitis, photoreceptor destruction and loss of visual function.[11]

An alternate method of disease induction is known as the adoptive transfer.[18] In this method, the disease is induced by injecting lymphocytes specific for retinal Ag. These Ags are taken from genetically compatible donors who had been immunized for EAU induction and are cultured in vitro with the Ag. The advantage of this method is that it does not require an adjuvant and the disease resembles the clinical situation in which the patient has circulating lymphocytes, which have been exposed to retinal Ags.[18]

**Genetics of experimental autoimmune uveitis susceptibility**

Susceptibility to EAU is genetically controlled. It has been observed that different species and strains within species, vary in their susceptibility. Thus, rats develop EAU after immunization with either S-Ag or IRBP. Guinea pigs are susceptible to S-Ag but not to IRBP, and mice develop severe disease with IRBP, but not with S-Ag.[19] Studies have shown that in order to develop EAU, a strain needs to have both a susceptible haplotype and a permissive background.[19] The haplotypes that have been identified to be highly to moderately susceptible are H-2r, H-2k, and H-2b, in descending order.[19] Some of the examples of the strains of the mice that have these haplotypes are B10.R111, B10.BR and C57BL/6 respectively. However, the disease in these strains will only develop in the presence of a permissive background. Hence, if the strain has a susceptible haplotype and a nonpermissive background, the disease will be seen in an attenuated form or will not develop at all.

**Special models of experimental autoimmune uveitis**

_Humanized model of experimental autoimmune uveitis in human leukocyte antigen class II transgenic mice_

In this model the mice lack the murine MHC class II molecule 1-A and are made transgenic (Tg) for the human leukocyte Ag (HLA) class II molecules HLA DR3, –DR4, –DQ6 or DQ8. Of these 4 strains, HLA – DR3 Tg mice develop the most severe disease when immunized with S-Ag. These mice are Tg for a single HLA molecule, however, in humans several HLA class II molecules are expressed together. It was observed that double Tg mice expressing DQ6 + DR3 or DR3 + DQ8 alleles were more susceptible than the single Tg models. This is an indicator that different HLA molecules influence each other for the development of the disease process. These humanized EAU models thus promise to help to identify the antigenic molecules responsible for human uveitis.[20,21]

**Experimental melanin induced uveitis**

Antigenic extracts from melanin incite a disease that targets uvea, but not retina and presents as recurrent anterior uveitis (RAU) with choroiditis. This is seen in a very severe form in Albino Lewis rats who have promelanocytes, but no melanin pigment showing that the pigment is not the actual target of the disease. Experimental autoimmune anterior uveitis (EAAU) and Experimental melanin induced uveitis are elicited by injecting crude fractions of bovine RPE, iris and ciliary body.[22–24] EAAU is a well-established model of acute anterior uveitis, which
resembles the human disease clinically and pathologically.[23] It can be induced in Lewis rats with bovine melanin associated Ag from the iris and ciliary body. The resultant inflammation is present only in the anterior chamber. Collagen type 1 has also been reported as an Ag in EAU.[23]

A well-defined model with melanin associated Ag is experimental Vogt Koyanagi Harada (VKH) disease in rats by using recombinantly expressed tyrosinase-related proteins (TRPs).[26] TRPs are proteins involved in the biosynthesis of melanin. The uveitis thus seen resembles VKH disease.

Endotoxin induced uveitis
Endotoxin-induced uveitis is a very useful model for anterior uveitis. It is not an autoimmune process and is triggered by the injection of bacterial endotoxin lipopolysaccharides (LPS). In this model after an injection of LPS (subcutaneous or intraperitoneal) a rapid but short-lived anterior uveitis is seen within 24 h of the injection.[24] Endotoxin-induced uveitis in mice is typically milder than the one seen in Lewis rats. Although it is not known whether a similar type of disease exists in humans, this model has been very useful for studying the various aspects of the acute ocular inflammatory process and the different therapeutic interventions.

The models of myelin basic protein-induced RAU, uveitis induced with RPE membrane components (experimental autoimmune posterior uveitis = EAPU or RPE65 uveitis)[27,28] and lens-induced uveitis[29] are not in use currently.

An alternate model of experimental autoimmune uveitis induced with inter-photorceptor retinoid-binding-particle presented by dendritic cells
Dendritic cells (DCs) are the main Ag presenting cells capable of stimulating nascent T-cells. Recently a model of EAU induced by the infusion of DC has been developed. These DC had been harvested from the spleens of mice injected with Flt3L DNA and later matured in vitro with LPS + anti CD40 antibody and pulsed with IRBP peptide 161–180.[30] This EAU model differs from the classic EAU model immunologically, clinically and pathologically.

Mice with DC-EAU have a distinct appearance of the fundus, the lesions being punctate versus confluent in the conventional EAU model. The inflammatory infiltrate is neutrophilic in DC-EAU versus the monocytic infiltrate in CFA-EAU. The course of the disease is shorter, and the disease is milder in DC-EAU.

Spontaneous uveitis models
In these type of experimental models, the disease process is not triggered by the inoculation of the Ag but it develops spontaneously over a period without any triggering agent. Some of these models are:

Human transgenic mice
Szpak et al.[30] made a HLA-A29 Tg mouse that spontaneously develops a posterior uveitis that resembles birdshot choroidoretinopathy. The target Ag has not yet been identified yet.

R161H mice express a Tg T-cell receptor specific to IRBP residues 161–180 (IRBP161-180; amino acid sequence SGPIYISLYHPGNTILHVD) and spontaneously develop ocular inflammation by 5–6 weeks of age.[30]

Autoimmune regulator knockout mice
Autoimmune regulator (AIRE) is a transcription factor that has been shown to cause ectopic expression of many tissue Ags in the thymus.[31] This expression has been found useful to delete or anergise the T-cells that respond with high affinity to self-Ags.

Autoimmune regulator deficient mice fail to express various self-Ags like S-Ag, IRBP and other retinal Ags in their thymus. And over a period these AIRE deficient mice develop antibodies against IRBP and spontaneous uveitis.[32] Further, it has been seen that those AIRE deficient mice that do not express IRBP in their retina do not develop uveitis despite the fact that they express another potential target retinal Ags for uveitis.[33]

Table 2 presents the clinicopathological differences between the spontaneous and the induced models of EAU.[33]

Specific uveitis animal models
Some special experimental animal models have been developed over the past years which warrants a special mention.

Experimental animal model of cytomegalovirus retinitis
This model has been developed in the mice strain C5BL/6 which is susceptible to develop a retrovirus induced murine acquired immunodeficiency syndrome (AIDS) similar to AIDS.[34] These mice develop a retinitis 8–10 days after intraperitoneal inoculation with murine CMV, which is characterized by full-thickness retinal necrosis with viral inclusions and cytomegalocytes and is quite similar to CMV retinitis in humans with AIDS. The retinitis develops in 90% of the immune-deficient mice as compared to 8% of the normal mice.

This model has been used to study the use of cytokine immunotherapy in CMV retinitis.[35] It has been shown that treatment of immunosuppressed mice with polyethylene glycol-interleukin (IL-2) prior to inoculation with murine cytomegalovirus (MCMV) reduces the intraocular MCMV

### Table 2: Clinicopathological differences between the spontaneous and the induced models of EAU

| Type of model | Type of uveitis | Anterior chamber involvement | Type of lesions | Cellular infiltrates | ERG findings |
|---------------|----------------|-----------------------------|----------------|---------------------|--------------|
| IRBP induced (B10.RIII) | Monophasic and chronic posterior | Present | Diffuse retinal lesions | Extensive with exudates | Decline during acute and atrophy phase but partial recovery in the chronic phase |
| R161H (Tg) | Chronic posterior | Minimal | Focal retinal | Persistent cellular infiltrates | Decline during atrophy phase |
| AIRE knockout | Chronic posterior | Absent | Small focal retinal and choroidal | Less cellular infiltrates | Decline in atrophy phase |

EAU: Experimental autoimmune uveitis, ERG: Electroretinography, IRBP: Inter-photorceptor retinoid-binding protein, AIRE: Autoimmune regulator
replication and a decrease in the frequency of retinitis. This prospect has led to an exciting opportunity to explore the therapeutic effect of this cytokine in combination with ganciclovir to combat this potentially sight-threatening disease.

**Experimental animal ocular tuberculosis model**

Rao *et al.* [36] developed an animal model of ocular tuberculosis from haematogenous spread of *mycobacterium tuberculosis* following aerosol delivery of the bacilli to the lungs of Hartley strain guinea pigs. All the exposed animals developed pulmonary tuberculosis, and 42% had ocular lesions resembling the human disease.

The animals demonstrated primarily posterior uveitis followed by intermediate and limbal inflammation. All the sites showed granulomatous inflammation and some showed the presence of acid-fast bacilli detectable by quantitative polymerase chain reaction. The animals treated with anti-tubercular therapy (ATT) showed no granulomatous inflammation indicating the importance of systemic ATT in the treatment of ocular tuberculosis.

However, the lack of retinal vasculature in the retina of guinea pigs would make it impossible to study the retinal vasculitis pathogenesis in this model. Having said this, still this animal model holds a lot of promise for understanding the pathogenesis of ocular tuberculosis and to develop further treatments for this clinical conundrum.

**Cellular Mechanisms in Experimental Autoimmune Uveitis**

Experimental autoimmune uveitis is a T-cell mediated autoimmune disease model. It has been proven in several studies beyond doubt that Th1 cells represent the main effector phenotype in EAU. [37] The main evidence to this effect are: (i) There is an association in the mouse strains between susceptibility to develop EAU and genetic propensity to mount a Th1 (a high interferon [IFN]-γ) response to IRBP. (ii) Immune T-cells derived from EAU models that caused EAU in normal mice when infused, were able to produce high IFN-γ and low IL-4 in *vitro* when stimulated with IRBP. (iii) Immune T-cell populations that make less IFN-γ are nonuveitogenic, but can be converted into uveitogenic phenotype by culture with IL-12. [38]

All the above facts suggest a strong role of the Th1 cells as the main effector arm in the EAU.

However, a new effector T-cell phenotype was discovered recently which has been named after the cytokine IL-17. The name of the lineage has thus been coined as Th17. This lineage has been now hypothesized to play an important role in many autoimmune diseases, and several studies indicated its uveitogenic role in EAU. [39-42] In fact, the classical EAU model shows a mixture of Th1 and Th17 response i.e. both IFN-γ and cytokine IL-17 are produced with very little IL-4. However, IFN-γ predominates over IL-17 in not only the draining lymph nodes (periphery), but also in the target organ. [41] However, studies show that the disease development can be stopped by neutralization of only IL-17 and not IFN-γ, thereby indicating that the presence of IL-17 is more critical in the pathogenesis of the disease. IL-17 and Th17 effector response may also have a role in human uveitis, but additional studies are required to establish this association more concretely.

The assay of cytokines from the lymph nodes of DC-EAU models predominantly show an IFN-γ dominant response with low production of IL-17. [29] That IFN-γ has a functional importance is further supported by the fact that an infusion of uveitogenic DC into IFN-γ knockout mice failed to develop the disease although they developed a good Th17 response.

These findings thus show that EAU is driven by 2 effector arms, Th1 and Th17, depending on the model. The main difference lies in the manner in which the Ag is presented to the immune system. In CFA-EAU, the Ag is presented to the draining lymph nodes where the mycobacterial components of the adjuvant provide stimulation to the Ag presenting cells over a prolonged period of time. However in DC-EAU the stimulus is a more focused and limited type inciting a different type of response and disease.

Extrapolating this to human disease, it can be inferred that the dominant type of Th effector response depends on the milieu present during the initial recognition of the auto Ags by the immune system. The inciting agents leading to human uveitis are unknown, but if these EAU models are applicable to humans, the events surrounding the initial Ag exposure maybe critical to the nature of the subsequent disease. On-going trials targeting IL-17 in uveitis may soon provide answers to these questions.

**Grading of Experimental Autoimmune Uveitis in Rat and Mouse**

Clinical grading of EAU and histo-pathological grading has been reported by Caspi [43] separately in mouse and rat [Tables 3 and 4]. This can be quite widely used in animal models of uveitis in different therapeutic intervention.
Table 4: Scoring of EAU histopathologically in rat and mouse (adapted from Caspi et al.\textsuperscript{[43]})

| Grade | Criteria in the rat | Criteria in the mouse |
|-------|---------------------|------------------------|
| 0     | No disease; normal retinal architecture | No change |
| 0.5 (trace) | Mild inflammatory cell infiltration of the retina with or without photoreceptor damage with <1/4 of retinal section affected | Mild inflammatory cell infiltration; no tissue damage |
| 1     | Mild inflammation and/or photoreceptor outer segment damage with ≥1/4 of retinal tissue affected | Infiltration; retinal folds and focal retinal detachments; few small granulomas in choroid and retina, perivasculitis |
| 2     | Mild-to-moderate inflammation and/or lesion extending to the outer nuclear layer with ≥1/4 of retinal tissue affected | Moderate infiltration; retinal folds, detachments, and focal photoreceptor cell damage; small-to-medium-size granulomas, perivasculitis, and vasculitis |
| 3     | Moderate-to-marked inflammation and/or lesion extending to the inner nuclear layer with ≥1/4 of retinal tissue affected | Medium-to-heavy infiltration; extensive retinal folding with detachments, moderate photoreceptor cell damage; medium-size granulomatous lesions; subretinal neovascularization |
| 4     | Severe inflammation and/or full thickness retinal damage with ≥1/4 of retinal tissue affected | Heavy infiltration; diffuse retinal detachment with serous exudate and subretinal bleeding; extensive photoreceptor cell damage; large granulomatous lesions; subretinal neovascularization |

EAU: Experimental autoimmune uveitis

Table 5: Bird’s eye view of the different experimental animal models

| Type of model | Antigen used/method of induction | Example of model | Clinicopathological features |
|---------------|----------------------------------|------------------|-----------------------------|
| Induced models |                                  |                  |                             |
| Induced rat model of EAU | Retinal antigens in CFA or adoptive transfer | Arrestin induced model in lewis rats | Very severe panuveitis which is acute and self-limiting |
| Induced mouse models of EAU | Ocular antigens in CFA or adoptive transfer of immune cells from immunized donors to naïve recipients | EAU induced in B10.R111, B10.A and C5BL/6 with IRBP | Uveoretinitis which is chronic; Recurrences are seen in B10.A strain |
| Humanized Tg models (induced) | S-Ag in CFA | HLA-DR3 mice induced with S-Ag or its fragments | Posterior uveitis |
| DC-EAU | Infusion of antigen pulsed syngeneic DCs | B10.R111 mice are given splenic DC’s elicited with Flt3L, matured \textit{in vitro} and pulsed with IRBP p161-180 | Punctate chorioretinal lesions with predominantly neutrophilic infiltrate. Disease course is milder and shorter than classic EAU |
| EMIU, EAAU | TRP 1 and 2 | Rats inoculated with melanin components or TRP 1and 2 | VKH like illness with inflammation of anterior chamber, iris, ciliary body and choroid and fundus hypopigmentation |
| EIU | Bacterial LPS | Systemic injection of LPS in mice or rats or local intraocular injection in rabbits | Acute anterior uveitis. Rapid onset and short duration |
| Spontaneous models |                                  |                  |                             |
| AIRE knockout mice | Deficient central tolerance | AIRE deficient mice develop antibodies directed at IRBP | Posterior uveitis |
| Tg mice | Tg mice deficient for human HLA class 1 antigen associated with uveitis | HLA-A29 Tg mice | BRC develops at 8-12 months of age |
| Double Tg mice | Double Tg mice expressing a neo self-antigen in the retina and an antigen specific TCR | R161H mice | Develop spontaneous uveitis at 5-6 weeks of age |
| Some specific models |                                  |                  |                             |
| Experimental animal CMV retinitis model | MCMV inoculation in MAIDS affected mice | C5BL/6 mice with MAIDS inoculated intraperitoneally with MCMV | Full thickness retinal necrosis with viral inclusion bodies |

Contd...
Clinicopathological features

Antigen used/method of the chemokines, which are responsible for migration and development of EAU neutralization of IL-17 by monoclonal antibodies halts the against TNF-α, which lead to abortion of the disease process. Targeted therapies produced by the uveitogenic T-cells, which when neutralized may play a role in cell migration, also aborts EAU.

Anti-tumor necrosis factor (TNF) therapy, which has been approved and in clinical use. T-Cell targeted therapies to modulate disease in EAU models have been shown to be efficacious in clinic as well. T-Cell targeted therapies have also been shown to be efficacious in EAU.

Historically, therapeutic approaches used successfully to modulate disease in EAU models have been shown to be efficacious in clinic as well. T-Cell targeted therapies like Cyclosporine, FK506 and Rapamycin are already Food and Drug Administration approved and in clinical use. Anti-tumor necrosis factor (TNF) therapy, which has been efficacious in EAU has been used clinically with good results in sero-negative spondyloarthropathies and juvenile idiopathic arthritis. IFN-α is being used with relative success to treat uveitis in Behçet’s disease.

The EAU model has given insights into the effector cytokines produced by the uveitogenic T-cells, which when neutralized lead to abortion of the disease process. Targeted therapies against TNF-α are already in clinical use. The finding that neutralization of IL-17 by monoclonal antibodies halts the development of EAU is being already investigated and clinical trials are underway to explore this as a therapeutic possibility.

Other potential targets are the adhesion molecules and the chemokines, which are responsible for migration and recruitment of inflammatory cells. The blockage of integrin very late activation Ag-4 (VLA-4) inhibits EAU in mice. This VLA-4 specific monoclonal antibody is already in use in Crohn’s disease and multiple sclerosis and is being evaluated for use in uveitis. Similarly, blocking of the integrin lymphocyte function-associated Ag 1 or its ligand intercellular adhesion molecule 1 inhibits EAU as does blockage of CD44. Blockage of chemokine receptors chemokine receptor type 3 (CXCR3) and CXCR5, which play a role in cell migration, also aborts EAU.

Conclusions

Uveitis is comprised of a variety of a heterogeneous group of disorders with ambiguous etiology and pathogenesis. The etiologic triggers of most types of uveitis are still unknown. Because of the limitation of ocular tissue available for studies, animal models of uveitis have been a wonderful resource to us for studying and understanding this mystifying group of diseases.

The EAU model has greatly increased our knowledge in understanding the whole mechanism of development of the human uveitis at both molecular and genetic level. The various advances in the types of animal models like the Tg mice and the DC-EAU models have helped us further broaden our perspective about the pathogenesis of the disease. Numerous therapeutic agents have been developed using the EAU model, which have been put into successful clinical use. However, the search for the “wonder drug,” which will target the retinal Ag specific T-cells that drive the disease is still on. There is a wide scope for further studies in this direction.

References

1. Gery I, Nussenblatt RB, Chan CC, Caspi RR. Autoimmune diseases of the eye. In: Theofilopoulos AN, Bona CA, editors. The Molecular Pathology of Autoimmune Diseases. New York: Taylor and Francis; 2002. p. 978-998.
2. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; The Northern California Epidemiology of Uveitis Study. Ophthalmology 2004;111:491-500.
3. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: Fundamentals and Clinical Practice. 2nd ed. St. Louis: Mosby/Year Book; 1996.
4. Gery I, Mochizuki M, Nussenblatt RB. Retinal specific antigens and immunopathogenic processes they provoke. Prog Retin Res 1986;5:75-109.
5. Agarwal RK, Caspi RR. Rodent models of experimental autoimmune uveitis. Methods Mol Med 2004;102:395-419.
6. Caspi RR, Chan CC, Wiggert B, Chader GJ. The mouse as a model of experimental autoimmune uveoretinitis (EAU). Curr Eye Res 1990;9 Suppl: 169-74.
7. Forrester JV, Liversidge J, Dua HS, Dick A, Harper F, McEnamin PG. Experimental autoimmune uveoretinitis: A model system for immunointervention: A review. Curr Eye Res 1992; 215‑301.

8. Silver PB, Chan CC, Wiggert B, Caspi RR. The requirement for pertussis to induce EAU is strain-dependent: B10.RII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment. Invest Ophthalmol Vis Sci 1999;40:2898-905.

9. Aronson SB, Hogan MJ, Zweigart P. Homoimmune uveitis in the guinea-pig. General concepts of auto-and homoimmunitiy, methods and manifestations. Arch Ophthalmal 1963;69:105-9.

10. Faure JP. Autoimmunity and the retina.Curr Top Eye Res 1980;2:215-301.

11. Silver PB, Chan CC, Wiggert B, Caspi RR. The requirement for pertussis to induce EAU is strain-dependent: B10.RII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment. Invest Ophthalmol Vis Sci 1999;40:2898-905.

12. Chan CC, Capri RR, Ni M, Leake WC, Wiggert B, Chader GJ, et al. Pathology of experimental autoimmune uveoretinitis in mice. J Autoimmun 1990;3:247-55.

13. Gery I, Chanaud NP. Angiela E. Recoverin is highly uveitogenic in Lewis rats. Invest Ophthalmol Vis Sci 1994;35:3342-5.

14. Danner S, Lohse MJ. Phosducin is a ubiquitous G-protein regulator. Proc Natl Acad Sci U S A 1996;93:10145-50.

15. Aronson SB, Hogan MJ, Zweigart P. Homoimmune uveitis in the guinea-pig. General concepts of auto-and homoimmunitiy, methods and manifestations. Arch Ophthalmal 1963;69:105-9.

16. Faure JP. Autoimmunity and the retina. Curr Top Eye Res 1982;215‑301.

17. Silver PB, Chan CC, Wiggert B, Caspi RR. The requirement for pertussis to induce EAU is strain-dependent: B10.RII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment. Invest Ophthalmol Vis Sci 1999;40:2898-905.

18. Mochizuki M, Kuwabara T, McAllister C, Nussenblatt RB, Gery I. Adoptive transfer of experimental autoimmune uveoretinitis in rats. Immunopathogenic mechanisms and histologic features. Invest Ophthalmol Vis Sci 1985;26:1-9.

19. Caspi RR, Grubbs BG, Chan CC, Chader GJ, Wiggert B. Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes. J Immunol 1992;148:2384-9.

20. Szpak Y, Vieville JC, Tabary T, Naud MC, Chopin M, Edelson C, et al. Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci U S A 2001;98:2572-6.

21. Pennesi G, Mattapallil MJ, Sun SH, Avicchez D, Silver PB, Karabekian Z, et al. A humanized model of experimental autoimmune uveoretinitis in HLA class II transgenic mice. J Clin Invest 2003;111:1171-80.

22. Broekhuysen RM, Kuhlmann ED, Winkens HJ. Experimental melanin-protein induced uveitis (EMIU) is the sole type of uveitis evoked by a diversity of ocular melanin preparations and melanin-derived soluble polypeptides. Jpn J Ophthalmol 1996;40:459-68.

23. Broekhuysen RM, Kuhlmann ED, Winkens HJ. Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium. Exp Eye Res 1992;55:401-11.

24. Smith JR, Hart PH, Williams KA. Basic pathogenic mechanisms operating in experimental models of acute anterior uveitis. Immunol Cell Biol 1996;74:497-512.

25. Bora NS, Sohn JS, Kang SG, Cruz JM, Nishihori H, Suk JH, et al. Type I collagen is the autoantigen in experimental autoimmune anterior uveitis. J Immunol 2004;172:7086-94.

26. Yamaki K, Kondo J, Nakamura H, Miyano M, Konno S, Sakuragi S. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res 2000;71:361-9.

27. Broekhuysen RM, Kuhlmann ED, Winkens HJ. Experimental autoimmune posterior uveitis accompanied by epitheliell cell accumulations (EAPU). A new type of experimental ocular disease induced by immunization with PEP-65, a pigment epithelial polypeptide preparation. Exp Eye Res 1992;55:819-29.

28. Ham DI, Gentleman S, Chan CC, McDowell JH, Redmond TM, Gery I. RPE65 is highly uveitogenic in rats. Invest Ophthalmol Vis Sci 2002;43:2258-63.

29. Tang J, Zhu W, Silver PB, Su SB, Chan CC, Caspi RR. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: Initial encounter with autostaining each defines disease phenotype. J Immunol 2007;178:8578-87.

30. Horai R, Silver PB, Agarwal RK, Mattapallil MJ, Natarajan K, Caspi RR, et al. Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a retina-specific T cell receptor. Int Immunol 2010;22:21.

31. DeVoss J, Hou Y, Johannes K, Lu W, Liou GJ, Rinn J, et al. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med 2006;203:2727-35.

32. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002;298:1395-401.

33. Chen J, Qian H, Horai R, Chan CC, Fatcik Y, Caspi RR. Comparative analysis of induced vs. spontaneous models of autoimmunity uveitis targeting the interphotoreceptor retinoid binding protein. PLoS One 2013;8:e72161.

34. Dix RD, Cray C, Cousins SW. Mice immunosuppressed by murine retrovirus infection (MAIDS) are susceptible to cytomegalovirus retinitis. Curr Eye Res 1994;13:387-95.

35. Dix RD, Giedlin M, Cousins SW. Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency. Invest Ophthalmol Vis Sci 1997;38:1411-7.

36. Rao NA, Albini TA, Kumaradas M, Pinn ML, Fraig MM, Karakousis PC. Experimental ocular tuberculosis in guinea pigs. Arch Ophthalmal 2009;127:1162-6.

37. Gregerson DS. Peripheral expression of ocular antigens in regulation and therapy of ocular autoimmunity. Int Rev Immunol 2002;21:101-21.

38. Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveoretinitis. J Immunol 1998;161:122-7.

39. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of ocular autoimmunity. Int Rev Immunol 2007;26:33-40.

40. Karabekian ZA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of ocular autoimmunity. Int Rev Immunol 2007;26:33-40.

41. Gregerson DS. Peripheral expression of ocular antigens in regulation and therapy of ocular autoimmunity. Int Rev Immunol 2002;21:101-21.

42. Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveoretinitis. J Immunol 1998;161:122-7.

43. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: Related but functionally distinct regulators of inflammation. Annu Rev Immunol 2007;25:221-42.

44. Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Oxsanblatt RB, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007;13:711-8.

45. Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category. J Exp Med 2008;205:799-810.

46. Peng Y, Han G, Shao H, Wang Y, Kaplan HJ, Sun D. Characterization of IL-17+interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2007;48:4153-61.

47. Caspi RR. Understanding autoimmunity in the eye: From animal models to novel therapies. Discov Med 2014;17:155-62.

48. Xu H, Koch P, Chen M, Lau A, Reid DM, Forrester J. A clinical grading system for retinal inflammation in the chronic model...
of experimental autoimmune uveoretinitis using digital fundus images. Exp Eye Res 2008;87:319-26.

45. Harimoto K, Ito M, Karasawa Y, Sakurai Y, Takeuchi M. Evaluation of mouse experimental autoimmune uveoretinitis by spectral domain optical coherence tomography. Br J Ophthalmol 2014;98:808-12.

46. Nussenblatt RB. Bench to bedside: New approaches to the immunotherapy of uveitic disease. Int Rev Immunol 2002;21:273-89.

47. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004;23:617-37.

48. Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: Anti-TNFalpha therapies in uveitis: Perspective on 5 years of clinical experience. Ocul Immunol Inflamm 2009;17:403-14.

49. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007;18:481-6.

50. Martin AP, de Moraes LV, Tadokoro CE, Commodaro AG, Urrets-Zavalia E, Rabinovich GA, et al. Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2005;46:2056-63.

51. Whitcup SM, DeBarge LR, Caspi RR, Harning R, Nussenblatt RB, Chan CC. Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol 1993;67:143-50.

52. Xu H, Manivannan A, Liversidge J, Sharp PF, Forrester JV, Crane IJ. Involvement of CD44 in leukocyte trafficking at the blood-retinal barrier. J Leukoc Biol 2002;72:1133-41.

53. Crane IJ, Xu H, Wallace C, Manivannan A, Mack M, Liversidge J, et al. Involvement of CCR5 in the passage of Th1-type cells across the blood-retina barrier in experimental autoimmune uveitis. J Leukoc Biol 2006;79:435-43.

Cite this article as: Bansal S, Barathi VA, Iwata D, Agrawal R. Experimental autoimmune uveitis and other animal models of uveitis: An update. Indian J Ophthalmol 2015;63:211-8.

Source of Support: Nil. Conflict of Interest: None declared.